AKR1C3 and urinary bladder carcinoma: Recently, Ramana et al. [121] provided evidence to show that AKR1C3 inhibitors restored chemosensitivity in gemcitabine and cisplatin-resistant bladder cancer cells by suppressing androgen signaling.